Skip to main content

Table 3 Multivariable logistic regression for factors associated with the utilization of disease-modifying treatment in 10,091 individuals administered digoxin and diuretics for chronic heart failure

From: Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database

Predictors of utilization Disease-modifying treatments group ACEI or ARB and Beta-blockers ACEI or ARB Beta-blockers Aldosterone antagonist
  (84.8% total) (26.9% total) (40.4% total) (8.5% total) (9.0% total)
  aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI) aPR (95% CI)
Older Age group   0.91 (0.84-0.97) 1.07 (1.01-1.14) 0.87 (0.78-0.96)  
Women   1.16 (1.05-1.29)    0.83 (0.71-0.97)
Specialty of healthcare providers being internal medicine 1.37 (1.09-1.71)   1.23 (1.01-1.49)   
Tertiary hospital 1.78 (1.49-2.12) 1.94 (1.73-2.16) 1.12 (1.03-1.22) 0.78 (0.68-0.88) 0.55 (0.48-0.64)
Urban residence 1.46 (1.23-1.74)   1.19 (1.09-1.29)   0.72 (0.62-0.84)
Outpatient prescription 3.87(2.95-4.57) 2.19 (1.95-2.46) 3.17 (2.75-3.64) 2.18 (1.80-2.64) 2.30 (1.69-3.05)
Cardiovascular disease
 Myocardial infarction   1.19 (1.03-1.36)    
 Transient ischemic stroke    0.78 (0.68-0.86)   1.51 (1.25-1.83)
 Arterial fibrillation or flutter 1.54 (1.28-1.84) 1.37 (1.24-1.51) 0.90 (0.83-0.99)   
 Valvular heart disease   1.23 (1.08-1.41)    0.71 (0.54-0.93)
Medical history
 Hypertension    1.10(1.02-1.22)   0.62 (0.53-0.73)
 Diabetes mellitus 1.32 (1.10-1.56)   1.09 (1.01-1.20)   0.84 (0.71-0.98)
 Hyperlipidemia or dyslipidemia     0.78 (0.65-0.93)  
 End-stage renal disease    0.78 (0.68-0.86)   
 Chronic lung disease   0.84 (0.76-0.93) 1.13 (1.03-1.23) 0.86 (0.74-0.93) 1.15 (1.00-1.34)
 Dementia 0.61 (0.42-0.90)   0.84 (0.70-0.99)   1.41 (1.09-1.82)
 Depression      
Concomitant medication
 CCB*   1.28 (1.15-1.42) 0.82 (0.75-0.90) 1.31 (1.13-1.53) 0.76 (0.64-0.90)
 Nitrates 1.39 (1.21-1.60) 1.33 (1.20-1.47)    0.73 (0.61-0.87)
 Inotropics 1.78 (1.48-2.16) 1.53 (1.37-1.69)   0.72 (0.60-0.86) 0.68 (0.56-0.83)
 Hydralazine   1.64 (1.14-2.37)    
 Lipid-lowering agents 1.93 (1.52-2.48) 1.61 (1.43-1.83)    0.46 (0.34-0.62)
 Anti-diabetic medication   1.14 (1.01-1.25)    
 Anti-thrombotics 1.63 (1.35-1.96) 1.55 (1.37-1.75)    0.59 (0.49-0.67)
  1. Adjusted for demographic factors (age, gender, residence area, utilization of hospital type, specialty of health care providers and type of prescription resources), previous cardiovascular diseases (angina, myocardial infarction, valvular heart disease, atrial fibrillation or flutter, transient ischemic attack), systemic medical diseases (hypertension, hyperlipidemia, chronic lung disease, end stage renal disease) and concomitant medications (heart failure medication, antidiabetic drugs).
  2. aPR; adjusted Prevalent Ratio, CI: Confidence Interval, CCB: Calcium channel blockers.